Evidence & regulatory context
- Mechanism
- No ChEMBL mechanism-of-action table record; flagged in ChEMBL as a chemical probe (chemical_probe=1) with no assigned max_phase. Reported in the literature as a GSK-3 inhibitor; not asserted from ChEMBL here.
- Target
- Not recorded
- Injury models
- Radiation · Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL max phase
- Not recorded
- Synonyms
- SB 216763; SB-216763; SB216763
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 3
3 studies reported at therapy level; 3 evidence entries itemised.
MouseRadiationC57Bl/6, C3H, and TCF/Lef1-HIST1H2BB/EGFP Wnt reporter transgenics on C57Bl/6 backgroundMale and femalen = Crypt survival assay n = 5 mice per treatment group per dos…Subcutaneous18 mg/kg in 100% DMSO24 hours after irradiation
Model: X-ray total body irradiation (6.5 Gy C57Bl/6, 6 Gy C3H for survival; 4 Gy for progenitor recovery; 3 Gy for Wnt reporter) and sub-total body irradiation with head and forelimb shielding (13 or 14 Gy for crypt survival; 14 and 15.55 Gy for gastrointestinal survival), 320 kVp, 12.5 mA
SB216763 improved 30 day survival and progenitor regeneration after total body irradiation in male C57Bl/6 mice only. There was no benefit in females of either strain, no significant benefit in C3H, no additional benefit over G-CSF plus ciprofloxacin, and no effect on gastrointestinal acute radiati…
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
MouseRadiationC57BL/6JSubcutaneous injection20 mg/kg single dose (BIO 30 mg/kg also tested in vivo)24 h after total-body irradiation
Model: Total-body irradiation (LD50/30 and 7 Gy LD70/30 doses) causing haematopoietic acute radiation syndrome
A single subcutaneous dose of SB216763 given 24 h after total-body irradiation improved haematopoietic recovery, increased KLS and colony-forming cell frequency, improved 30-day survival by 20 to 25 per cent and extended mean survival time from 13 to 22.5 days at 7 Gy.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
MouseChemical/toxinC57BL/6Jmale
Model: triptolide-induced acute cardiac injury in mice, with corroborating in vitro studies in triptolide-treated H9c2 cardiomyoblasts
Pharmacological inhibition of GSK-3beta with SB 216763 ameliorated triptolide-induced acute cardiac injury in mice and improved cell viability and reduced apoptosis in triptolide-treated H9c2 cells, via prevention of GSK-3beta-mediated cyclophilin F phosphorylation and desensitisation of the mitoch…
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
